Literature DB >> 8663582

Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling.

J F Feng1, S G Rhee, M J Im.   

Abstract

A new class of GTP-binding protein transglutaminase II (Gh) couples to a 69-kDa phospholipase C (PLC). An 8-amino acid region (Leu665-Lys672) of the alpha-subunit of Gh (Galphah) is involved in interaction and activation of PLC, an observation that has now been used to characterize the 69-kDa PLC further. A 20-amino acid peptide corresponding to Leu654-Leu673 of Galphah was used to prepare an affinity resin. On incubation with a partially purified PLC preparation from rat liver membranes, the affinity resin-bound approximately69- and 85-kDa proteins were recognized by an antibody to the 69-kDa PLC. Both purified 69-kDa PLC and PLC-delta1 bound to the affinity resin; moreover, antibodies to PLC-delta1 recognized the 69-kDa PLC, and antibodies to the 69-kDa PLC recognized PLC-delta1. A synthetic peptide corresponding to Leu661-Lys672 of Galphah inhibited the binding of PLC-delta1 to the affinity resin and also stimulated PLC-delta1. Reconstitution of PLC-delta1 with GTPgammaS (guanosine 5'-3-O-(thio)triphosphate)-activated Gh resulted in activation of PLC-delta1. Antibodies to Galphah also coimmunoprecipitated PLC-delta1 upon activation of Gh. These findings indicate that PLC-delta1 is the effector of Gh-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663582     DOI: 10.1074/jbc.271.28.16451

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling.

Authors:  J Zhang; J Tucholski; M Lesort; R S Jope; G V Johnson
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

2.  Nucleotide binding by the erythrocyte transglutaminase/Gh protein, probed with fluorescent analogs of GTP and GDP.

Authors:  S N Murthy; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 3.  The phospholipase C isozymes and their regulation.

Authors:  Aurelie Gresset; John Sondek; T Kendall Harden
Journal:  Subcell Biochem       Date:  2012

4.  The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization.

Authors:  Richard M Thomas; Cheryl A Nechamen; Joseph E Mazurkiewicz; Alfredo Ulloa-Aguirre; James A Dias
Journal:  Endocrinology       Date:  2011-02-01       Impact factor: 4.736

5.  Neurodegenerative diseases and transglutaminase.

Authors:  L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine.

Authors:  Ju-Hong Jeon; Kyung-Ho Choi; Sung-Yup Cho; Chai-Wan Kim; Dong-Myung Shin; Joon-Cheol Kwon; Kye-Yong Song; Sang-Chul Park; In-Gyu Kim
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

7.  Importance of Ca(2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis.

Authors:  Sunando Datta; Marc A Antonyak; Richard A Cerione
Journal:  Biochemistry       Date:  2006-11-07       Impact factor: 3.162

8.  A novel function of tissue-type transglutaminase: protein disulphide isomerase.

Authors:  Go Hasegawa; Motoi Suwa; Yasuo Ichikawa; Tetsuro Ohtsuka; Satoru Kumagai; Masashi Kikuchi; Yoshitaka Sato; Yuji Saito
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

9.  Phospholipase C-delta1 modulates sustained contraction of rat mesenteric small arteries in response to noradrenaline, but not endothelin-1.

Authors:  Christopher J Clarke; Simon Forman; James Pritchett; Vasken Ohanian; Jacqueline Ohanian
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

10.  Transglutaminase in Receptor and Neurotransmitter-Regulated Functions.

Authors:  Nancy A Muma
Journal:  Med One       Date:  2018-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.